MediciNova, Inc. (MNOV): Price and Financial Metrics


MediciNova, Inc. (MNOV): $3.21

-0.21 (-6.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNOV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 507

in industry

MNOV POWR Grades


  • Sentiment is the dimension where MNOV ranks best; there it ranks ahead of 86.86% of US stocks.
  • MNOV's strongest trending metric is Value; it's been moving up over the last 47 weeks.
  • MNOV's current lowest rank is in the Momentum metric (where it is better than 9.54% of US stocks).

MNOV Stock Summary

  • For MNOV, its debt to operating expenses ratio is greater than that reported by only 5.89% of US equities we're observing.
  • With a price/sales ratio of 41.54, Medicinova Inc has a higher such ratio than 94.46% of stocks in our set.
  • MNOV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.94% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Medicinova Inc are HRTX, BLI, CCXI, ADVM, and FREQ.
  • Visit MNOV's SEC page to see the company's official filings. To visit the company's web site, go to medicinova.com.

MNOV Valuation Summary

  • In comparison to the median Healthcare stock, MNOV's price/sales ratio is 322.03% higher, now standing at 47.9.
  • Over the past 179 months, MNOV's price/sales ratio has gone down 67.3.
  • MNOV's EV/EBIT ratio has moved down 7.4 over the prior 179 months.

Below are key valuation metrics over time for MNOV.

Stock Date P/S P/B P/E EV/EBIT
MNOV 2021-08-31 47.9 2.1 -17.2 -10.2
MNOV 2021-08-30 46.8 2.1 -16.8 -9.8
MNOV 2021-08-27 46.6 2.1 -16.7 -9.7
MNOV 2021-08-26 46.8 2.1 -16.8 -9.8
MNOV 2021-08-25 46.3 2.1 -16.6 -9.6
MNOV 2021-08-24 45.2 2.0 -16.2 -9.2

MNOV Growth Metrics

  • The 2 year cash and equivalents growth rate now stands at -2.56%.
  • Its 2 year price growth rate is now at -54.7%.
  • Its 5 year cash and equivalents growth rate is now at 177.8%.
MNOV's revenue has moved up $4,037,500 over the prior 52 months.

The table below shows MNOV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 4.0375 -7.691724 -11.0364
2021-06-30 4 -8.584199 -11.16105
2021-03-31 4 -11.80169 -11.32814
2020-12-31 0 -10.82636 -13.8539
2020-09-30 0 -11.28166 -12.8527
2020-06-30 0 -9.412566 -11.52738

MNOV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MNOV has a Quality Grade of D, ranking ahead of 17.27% of graded US stocks.
  • MNOV's asset turnover comes in at 0.047 -- ranking 325th of 680 Pharmaceutical Products stocks.
  • ACER, SCYX, and ATNM are the stocks whose asset turnover ratios are most correlated with MNOV.

The table below shows MNOV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.047 1 -2.232
2021-03-31 0.049 1 -2.359
2020-12-31 0.000 NA -3.663
2020-09-30 0.000 NA -3.396
2020-06-30 0.000 NA -3.088
2020-03-31 0.000 NA -2.751

MNOV Price Target

For more insight on analysts targets of MNOV, see our MNOV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.50 Average Broker Recommendation 1.33 (Strong Buy)

MNOV Stock Price Chart Interactive Chart >

Price chart for MNOV

MNOV Price/Volume Stats

Current price $3.21 52-week high $10.81
Prev. close $3.42 52-week low $3.03
Day low $3.19 Volume 272,626
Day high $3.40 Avg. volume 656,970
50-day MA $3.62 Dividend yield N/A
200-day MA $4.21 Market Cap 157.43M

MediciNova, Inc. (MNOV) Company Bio


MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. The company was founded in 2000 and is based in La Jolla, California.


MNOV Latest News Stream


Event/Time News Detail
Loading, please wait...

MNOV Latest Social Stream


Loading social stream, please wait...

View Full MNOV Social Stream

Latest MNOV News From Around the Web

Below are the latest news stories about Medicinova Inc that investors may wish to consider to help them evaluate MNOV as an investment opportunity.

MNOV: Addition of MN-166 to PD-1 Treatment Extends Survival in Preclinical GBM Model…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update MN-166 in Combination with PD-1 Inhibitor Extends Survival in Preclinical Model On November 22, 2021, MediciNova, Inc. (NASDAQ:MNOV) announced results from a preclinical study of MN-166 (ibudilast) in combination with a PD-1 inhibitor presented at the 26 th Annual Meeting of the Society for Neuro-Oncology (SNO).

Yahoo | November 23, 2021

MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology

LA JOLLA, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Le

Yahoo | November 22, 2021

We Think MediciNova (NASDAQ:MNOV) Can Easily Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | November 15, 2021

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

LA JOLLA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator Masatsune Ogura, M.D., Ph.D., Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, is presenting results and findings of a study that investigated the mechanism by whi

Yahoo | November 11, 2021

MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting

LA JOLLA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Grazia Ambrosini, PhD, an associate research scientist at Columbia University Vagelos College of Physicians and Surgeons, presented data regarding MN-166 (ibudilast) in a uveal melanoma (UM) model study at the 10 th Annual CURE OM Global Science Meeting held online as a part of the Society for Melanoma Research International Congress on October 28, 2021.

Intrado Digital Media | November 10, 2021

Read More 'MNOV' Stories Here

MNOV Price Returns

1-mo -4.46%
3-mo -22.28%
6-mo -21.32%
1-year -45.96%
3-year -67.77%
5-year -54.40%
YTD -38.97%
2020 -21.96%
2019 -17.50%
2018 26.28%
2017 7.30%
2016 69.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7343 seconds.